Orgenesis Inc. (ORGS)
USD 2.4
(10.6%)
USD 2.4
(10.6%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -53.63 Million USD | -627.96% |
| 2022 | -7.36 Million USD | 82.74% |
| 2021 | -42.68 Million USD | 55.44% |
| 2020 | -95.78 Million USD | -289.29% |
| 2019 | -24.6 Million USD | -67.95% |
| 2018 | -14.65 Million USD | -30.45% |
| 2017 | -11.23 Million USD | -199.58% |
| 2016 | 11.27 Million USD | 256.39% |
| 2015 | -7.21 Million USD | -57.56% |
| 2014 | -4.57 Million USD | 16.19% |
| 2013 | -5.46 Million USD | -9.46% |
| 2012 | -4.98 Million USD | -6794.85% |
| 2011 | -72.35 Thousand USD | -241.72% |
| 2010 | -21.17 Thousand USD | 17.45% |
| 2009 | -25.64 Thousand USD | -632.8% |
| 2008 | -3500.00 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -8.88 Million USD | 87.65% |
| 2024 Q2 | -4.06 Million USD | 54.19% |
| 2023 Q3 | -2.08 Million USD | 37.46% |
| 2023 Q1 | -3.2 Million USD | -1220.63% |
| 2023 FY | -53.63 Million USD | -627.96% |
| 2023 Q2 | -3.32 Million USD | -3.87% |
| 2023 Q4 | -71.92 Million USD | -3354.47% |
| 2022 Q1 | -3.23 Million USD | 87.88% |
| 2022 FY | -7.36 Million USD | 82.74% |
| 2022 Q4 | 286 Thousand USD | 201.42% |
| 2022 Q3 | -282 Thousand USD | 94.04% |
| 2022 Q2 | -4.73 Million USD | -46.23% |
| 2021 Q4 | -26.69 Million USD | -448.67% |
| 2021 Q1 | 81 Thousand USD | 100.15% |
| 2021 FY | -42.68 Million USD | 55.44% |
| 2021 Q3 | 7.65 Million USD | 430.14% |
| 2021 Q2 | -2.31 Million USD | -2962.96% |
| 2020 Q2 | -26.77 Million USD | -297.62% |
| 2020 Q1 | -6.73 Million USD | -1.22% |
| 2020 Q3 | -9.34 Million USD | 65.09% |
| 2020 Q4 | -52.93 Million USD | -466.34% |
| 2020 FY | -95.78 Million USD | -289.29% |
| 2019 Q3 | -4.42 Million USD | 15.78% |
| 2019 Q1 | -8.27 Million USD | -3.37% |
| 2019 Q2 | -5.25 Million USD | 36.49% |
| 2019 FY | -24.6 Million USD | -67.95% |
| 2019 Q4 | -6.65 Million USD | -50.33% |
| 2018 Q2 | -2.76 Million USD | 14.64% |
| 2018 FY | -14.65 Million USD | -30.45% |
| 2018 Q3 | -645 Thousand USD | 76.66% |
| 2018 Q4 | -8 Million USD | -1140.78% |
| 2018 Q1 | -3.23 Million USD | -58.11% |
| 2017 Q3 | -3.41 Million USD | -46.82% |
| 2017 Q4 | -2.04 Million USD | 39.98% |
| 2017 FY | -11.23 Million USD | -199.58% |
| 2017 Q2 | -2.32 Million USD | 32.56% |
| 2017 Q1 | -3.44 Million USD | -117.63% |
| 2016 FY | 11.27 Million USD | 256.39% |
| 2016 Q4 | 19.54 Million USD | 900.45% |
| 2016 Q3 | -2.44 Million USD | 38.54% |
| 2016 Q2 | -3.97 Million USD | -114.18% |
| 2016 Q1 | -1.85 Million USD | 19.24% |
| 2015 Q2 | -2.03 Million USD | -143.79% |
| 2015 Q3 | -2.04 Million USD | -0.46% |
| 2015 FY | -7.21 Million USD | -57.56% |
| 2015 Q4 | -2.29 Million USD | -12.36% |
| 2015 Q1 | -834.7 Thousand USD | -37.18% |
| 2014 Q1 | -1.11 Million USD | 33.72% |
| 2014 Q4 | -608.47 Thousand USD | 52.67% |
| 2014 FY | -4.57 Million USD | 16.19% |
| 2014 Q3 | -1.28 Million USD | 17.86% |
| 2014 Q2 | -1.56 Million USD | -40.1% |
| 2013 Q3 | -1.16 Million USD | 10.07% |
| 2013 Q1 | -1.32 Million USD | 3.69% |
| 2013 FY | -5.46 Million USD | -9.46% |
| 2013 Q4 | -1.68 Million USD | -45.05% |
| 2013 Q2 | -1.29 Million USD | 2.12% |
| 2012 FY | -4.98 Million USD | -6794.85% |
| 2012 Q4 | -1.37 Million USD | 27.43% |
| 2012 Q3 | -1.88 Million USD | -115.94% |
| 2012 Q2 | -874.82 Thousand USD | -2.47% |
| 2012 Q1 | -853.76 Thousand USD | -1278.9% |
| 2011 Q1 | -5436.00 USD | 31.98% |
| 2011 FY | -72.35 Thousand USD | -241.72% |
| 2011 Q4 | -61.91 Thousand USD | -2163.84% |
| 2011 Q3 | -2735.00 USD | -20.75% |
| 2011 Q2 | -2265.00 USD | 58.33% |
| 2010 Q4 | -7992.00 USD | -44.99% |
| 2010 Q3 | -5512.00 USD | -12.72% |
| 2010 FY | -21.17 Thousand USD | 17.45% |
| 2010 Q2 | -4890.00 USD | -75.96% |
| 2010 Q1 | -2779.00 USD | 45.14% |
| 2009 Q1 | -1706.00 USD | 0.0% |
| 2009 Q4 | -5066.00 USD | 62.16% |
| 2009 Q3 | -13.38 Thousand USD | -144.06% |
| 2009 FY | -25.64 Thousand USD | -632.8% |
| 2009 Q2 | -5486.00 USD | -221.57% |
| 2008 FY | -3500.00 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | -10787.375% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | -463.522% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | -78.828% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 20.117% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | -238.547% |
| Better Therapeutics, Inc. | -38.26 Million USD | -40.181% |
| Calithera Biosciences, Inc. | -42.07 Million USD | -27.48% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | -348.086% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | -58.48% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | -55.833% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 50.55% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | -2562.759% |
| Finch Therapeutics Group, Inc. | -34 Million USD | -57.744% |
| Galera Therapeutics, Inc. | -46.95 Million USD | -14.238% |
| Innovation1 Biotech Inc. | -1.36 Million USD | -3822.521% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | -168.996% |
| Molecular Templates, Inc. | -10.46 Million USD | -412.479% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | -281.727% |
| NexImmune, Inc. | -29.19 Million USD | -83.732% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -4.566% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -68649.119% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -232.209% |
| Scopus BioPharma Inc. | -11.71 Million USD | -357.845% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 89.365% |
| Statera Biopharma, Inc. | -98.34 Million USD | 45.461% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | -677.559% |
| Trevena, Inc. | -35.28 Million USD | -51.995% |
| Vaxxinity, Inc. | -58.28 Million USD | 7.976% |
| Vaccinex, Inc. | -22.88 Million USD | -134.372% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | -5022.935% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | -5.806% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -638.482% |